🇺🇸 FDA
Pipeline program

Selective serotonin reuptake inhibitor (SSRI)

2025CN019

Approved small_molecule active

Quick answer

Selective serotonin reuptake inhibitor (SSRI) for Anxiety Depression is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Anxiety Depression
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials